Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

My connections

CLINICAL TRIALS

1.  Low dosE GlibENclamide in Diabetes Part A (LEGEND-A), NCT02830048

2. Glucagon in MODY, NCT03246828

 

Upcoming:

  • Dapagliflozin during Exercise for the Prevention of Hypos (DEPTH)

Ioannis Spiliotis

MBBS, BSc, MRCP (UK)


Clinical Research Fellow & DPhil student

  • Honorary Specialty Registrar in Diabetes and Endocrinology

I am a clinical researcher and Specialty Registrar in Diabetes and Endocrinology, with a background in molecular biology. I have been working in the field of islet physiology since 2010 alongside my clinical training, and am currently  completing a DPhil in OCDEM. I am also part of the clinical Islet Transplantation programme.

My work focuses on investigating the hormone secretion profiles of islets in various forms of diabetes, with an emphasis on translating in vitro work into pilot clinical trials. I have recently completed a clinical trial (LEGEND-A) of low-dose sulfonylureas in patients with type 2 diabetes, which demonstrated improvement in fasting hyperglucagonemia. I am now extending this work to clinical studies in patients with MODY (maturity onset diabetes of the young) and type 1 diabetes. My aim is to better understand the effect aberrant glucagon secretion has on the pathophysiology of diabetes, and the impact various pharmacological interventions have on this system.

False False

5 View 1 more »

Diabetes, fat and sugar – behind the headlines